Chemours Co
boothcheck covers Chemours Co (CC) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed July 25, 2026.
• Three businesses share one ticker: titanium dioxide at 40% of revenue, the refrigerant lines of Opteon, Freon and foam blowing agents at about 35% together, and advanced materials at roughly 23%, and only the refrigerant side is currently growing. • Leverage is the governing fact, with about 3.61 billion dollars of net debt and a March refinancing that put 700 million dollars of 7.875% senior unsecured notes due 2034 in place of 5.375% and 5.750% paper [Source: company 8-K, March 12, 2026]. •
Is CC overvalued? See what's priced in →
436 institutional managers reported holding CC in 13F filings for the quarter ended 2026-03-31. Together they hold about 85% of the company; the top 10 hold 48%. 73 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 10.2M shares were sold short as of the 2026-06-15 count, about 7% of shares outstanding (5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CC has cut its share count 9.3% over the past five years, spending $728.00M on repurchases. It pays a dividend, and has paid one every year in our records (11 and counting); the current rate is $0.51 a share annually. Cash returned over the past three years: $313.00M in dividends and $18.00M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at CC over the trailing three years: 2025: 4 buys totaling $301k. 24 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CC's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-29 | -3.6% | -23.4% |
| 2023-10-28 | -0.1% | +33.7% |
| 2024-03-28 | +1.8% | -2.6% |
| 2024-05-01 | -6.3% | -12.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CC's latest 8-K filings: 2026-09-10 (items 1.01, 7.01, 9.01); 2026-09-09 (items 7.01, 9.01); 2026-08-04 (items 2.02, 9.01); 2026-06-24 (items 1.01, 7.01, 9.01); 2026-05-05 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.